Trial · NCT05205668
Study of F-652 in Subjects With Corona Virus Disease 2019 (COVID-19) Pneumonia
NCT05205668, Phase 2, Withdrawn, EVIVE Biotechnology
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of F-652 in Subjects With Corona Virus Disease 2019 (COVID-19) Pneumonia. Trials, record NCT05205668. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05205668
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of F-652 in Subjects With Corona Virus Disease 2019 (COVID-19) Pneumonia
- NCT number
- NCT05205668
- Status
- Withdrawn
- Phases
- Phase 2
- Enrollment
- 0 participants, actual
- Lead sponsor
- EVIVE Biotechnology
- Conditions
- COVID-19 Pneumonia
- Interventions
- F-652, Placebo
- First posted
- 2022-01-25
- Last updated
- 2023-10-02
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The proportion of subjects with any treatment-emergent adverse events (TEAEs) during the study | Day 1 to Day 60/End of Study (EOS) | |
| Secondary | Proportion (%) of subjects with any serious adverse events (SAEs) and drug-related adverse events (AEs) during the study | Day 1 to Day 60/EOS | |
| Secondary | Proportion (%) of subjects with clinically significant abnormality in clinical laboratory tests and ECG during the study | Day 1 to Day 28 | |
| Secondary | Change in parameters for coagulopathy including D-dimer, fibrinogen, coagulation tests and platelet count during the study | Day 1 to Day 28 | |
| Secondary | Change in parameters of cardiac function including N-terminal-pro hormone brain natriuretic peptide (NT-proBNP) or brain natriuretic peptide (BNP) and high-sensitivity cardiac troponin (or troponin) during the study | Day 1 to Day 28 | |
| Secondary | Serum concentration of F-652 at specified timepoints | At predefined timepoints from Day 1 to Day 14/End of Treatment (EOT) | |
| Secondary | Number of days with oxygen use during the treatment period | Day 1 to Day 14/EOT | |
| Secondary | Change in the World Health Organization (WHO) 10-point ordinal scale during the study period | Day 1 to Day 14/EOT and Day 28 | The World Health Organization 10-point ordinal scale is developed by a special committee at WHO to measure illness severity over time. The minimum value is 0, the maximum value is 10. Severity increases as the score increases. A 2-point reduction on the score is considered as clinical improvement. |
| Secondary | Number of days hospitalized during the treatment period | Day 1 to Day 14/EOT | |
| Secondary | Proportion (%) of subjects alive and free of respiratory failure during the study period | Day 1 to Day 14/EOT, Day 28, and Day 60/EOS |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05205668
GET https://conductscience.org/api/trials/v1/NCT05205668/registered